Cancer Cell Biology

You have full text access to this OnlineOpen article

PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors

  1. Alexander V. Timoshenko1,
  2. Peeyush K. Lala1,
  3. Chandan Chakraborty1,2,†,*

Article first published online: 28 OCT 2003

DOI: 10.1002/ijc.11575

Issue

International Journal of Cancer

International Journal of Cancer

Volume 108, Issue 3, pages 384–389, 20 January 2004

Additional Information

How to Cite

Timoshenko, A. V., Lala, P. K. and Chakraborty, C. (2004), PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. Int. J. Cancer, 108: 384–389. doi: 10.1002/ijc.11575

Author Information

  1. 1

    Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada

  2. 2

    Department of Pathology, University of Western Ontario, London, Ontario, Canada

  1. †

    Fax: +519-661-3370

*Department of Pathology, University of Western Ontario, London, Ontario, N6A 5C1, Canada

Publication History

  1. Issue published online: 21 NOV 2003
  2. Article first published online: 28 OCT 2003
  3. Manuscript Accepted: 26 AUG 2003
  4. Manuscript Revised: 28 JUL 2003
  5. Manuscript Received: 26 MAY 2003

Funded by

  • Canadian Breast Cancer Research Alliance. Grant Number: 012312
  • Breast Cancer Society of Canada

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (200K)

REFERENCES

  • 1
    Di Rosa M, Ialenti A, Ianaro A, Sautebin L. Interaction between nitric oxide and cyclooxygenase pathways. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 229–38.
  • 2
    Salvemini D. Cyclooxygenase: an important transduction system for the multifaceted roles of nitric oxide. In: RubanyiGM, editor. Pathophysiology and clinical applications of nitric oxide. part A. Amsterdam: Harwood Academic, 1999. 155–70.
  • 3
    Weinberg JB. Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. Immunol Res 2000; 22: 319–41.
  • 4
    Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001; 7: 1325–32.
  • 5
    Klimp AH, Hollema H, Kempinga C, van der Zee AGJ, de Vries EGE, Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 2001; 61: 7305–9.
  • 6
    Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001; 29: 23–8.
  • 7
    Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632–5.
  • 8
    Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11–21.
  • 9
    Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001; 93: 497–506.
    Direct Link:
  • 10
    Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362–6.
  • 11
    Lala PK, Saarloos MN. Prostaglandins and the host immune system: application of prostaglandin inhibitors for cancer immunotherapy. In: HarrisJE, BraunDP, AndersonKM, editors. Prostaglandin inhibitors in tumor immunology and immunotherapy. Boca Raton: CRC Press, 1994. 187–227.
  • 12
    Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661–90.
  • 13
    Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2: 149–56.
  • 14
    Milas L, Wike J, Hunter N, Volpe J, Basic I. Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability. Cancer Res 1987; 47: 1069–75.
  • 15
    Thomsen LL, Miles DW. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 1998; 17: 107–18.
  • 16
    Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 2000; 6: 2408–16.
  • 17
    Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995; 72: 41–4.
  • 18
    Lala PK, Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 1998; 17: 91–106.
  • 19
    Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, Lala PK. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 1999; 81: 889–96.
    Direct Link:
  • 20
    Jadeski LC, Lala PK. Nitric oxide synthase inhibition by NG-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999; 155: 1381–90.
  • 21
    Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000; 86: 30–9.
    Direct Link:
  • 22
    Jadeski LC, Chakraborty C, Lala PK. Role of nitric oxide in tumour progression with special reference to a murine breast cancer model. Can J Physiol Pharmacol 2002; 80: 125–35.
  • 23
    Jadeski LC, Chakraborty C, Lala PK. Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int J Cancer 2003; 106: 496–504.
    Direct Link:
  • 24
    Lala PK, Parhar RS. Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy. Int J Cancer 1993; 54: 677–84.
    Direct Link:
  • 25
    Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res, 2003; 289: 265–74.
  • 26
    Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, Sheldrick RL. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 1994; 47: 151–68.
  • 27
    Balsinde J, Winstead MV, Dennis EA. Phospholipase A2 regulation of arachidonic acid mobilization. FEBS Lett 2002; 531: 2–6.
  • 28
    Yamada K, Okano Y, Miura K, Nozawa Y. Arachidonic acid release in BW755C-pretreated rat peritoneal mast cells stimulated with A23187, concanavalin A and compound 48/80. Biochim Biophys Acta 1987; 917: 290–5.
  • 29
    Ferm MT, Soderstrom K, Jindal S, Gronberg A, Ivanyi J, Young R, Kiessling R. Induction of human hsp60 expression in monocytic cell lines. Int Immunol 1992; 4: 305–11.
  • 30
    Billack B, Heck DE, Mariano TM, Gardner CR, Sur R, Laskin DL, Laskin JD. Induction of cyclooxygenase-2 by heat shock protein 60 in macrophages and endothelial cells. Am J Physiol Cell Physiol 2002; 283: C1267–77.
  • 31
    Galea E, Feinstein DL. Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J 1999; 13: 2125–37.
  • 32
    Cieslik K, Zhu Y, Wu KK. Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway. J Biol Chem 2002; 277: 49304–10.
  • 33
    Saunders MA, Sansores-Garcia L, Gilroy DW, Wu KK. Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. J Biol Chem 2001; 276: 18897–904.
  • 34
    Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci USA 1999; 96: 5292–7.
  • 35
    Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002; 62: 165–70.
  • 36
    Nasrallah R, Laneuville O, Ferguson S, Hébert RL. Effect of COX-2 inhibitor NS-398 on expression of PGE2 receptor subtypes in M-1 mouse CCD cells. Am J Physiol 2001; 281: F123–32.
View Full Article (HTML) Get PDF (200K)